aXichem AB Class A (AXIC.A) AI Stock Analysis

• Market Cap: €164.34M
• Dividend Yield: N/A
• Average Volume (3M): 42.80K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: 64.85%
• EPS Growth: 44.62%
• Country: SE
• Employees: 7
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.06
• Shares Outstanding: 59,114,906
• 10 Day Avg. Volume: 40,428
• 30 Day Avg. Volume: 42,804
• PEG Ratio: 0.06
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 7.31
• P/FCF Ratio: -5.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 59 Neutral
• Price Target: ―

aXichem AB Class A shows strong revenue growth, but its profitability and cash flow issues weigh heavily on its financial performance score. The technical analysis suggests positive momentum, potentially offering short-term bullish opportunities. However, the poor valuation due to unprofitability and the absence of dividends affects the overall attractiveness of the stock.

aXichem AB Class A Business Overview & Revenue Model

Company Description

aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, an natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was incorporated in 2007 and is based in Malmö, Sweden.

How the Company Makes Money

aXichem AB generates revenue primarily by selling its synthetic capsaicin products to companies operating in the health, feed, and food industries. The company's key revenue streams include direct sales of its products to manufacturers who incorporate these ingredients into their own offerings, such as dietary supplements, animal feed, and food products. Additionally, aXichem may engage in licensing agreements and partnerships with other companies to expand the reach and application of its technology. These collaborations can provide additional income through licensing fees and shared revenue models. Factors contributing to aXichem's earnings include the growing demand for natural and sustainable ingredients in various industries and the company's ability to innovate and adapt its products to meet market needs.

aXichem AB Class A Financial Statement Overview

Summary

aXichem AB Class A shows strong revenue growth potential but struggles with profitability and cash flow management. The balance sheet is robust with no debt, providing financial stability. However, consistent negative cash flow and net income highlight the need for strategic operational improvements to achieve profitability.

Income Statement

aXichem AB Class A has shown substantial revenue growth over the years, with a significant increase from SEK 1.8 million in 2023 to SEK 8.57 million in 2024. However, the company is struggling with profitability issues, as evidenced by consistently negative EBIT and net income margins. The gross profit margin is healthy, but the negative net profit margin indicates high operational and other costs impacting the bottom line.

Balance Sheet

The company maintains a solid financial structure with no debt as of 2024, resulting in a Debt-to-Equity ratio of zero. This indicates a strong equity position, further supported by a high equity ratio of 94.4%. While net income remains negative, the return on equity is affected, but the absence of debt reduces financial risk considerably.

Cash Flow

Operating cash flow remains negative, though improved from 2023. The company managed to significantly increase its cash position through financing activities. However, the free cash flow remains negative, indicating ongoing cash consumption from operations despite growth in revenue.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.93M	8.57M	1.81M	5.01M	4.36M	1.23M
Gross Profit	7.06M	7.08M	1.41M	3.82M	909.00K	596.00K
EBITDA	-15.10M	-11.55M	-15.10M	-12.44M	-13.49M	-12.01M
Net Income	-20.51M	-17.81M	-20.81M	-17.26M	-15.09M	-13.52M
Balance Sheet
Total Assets	68.18M	74.28M	61.49M	61.25M	58.77M	55.75M
Cash, Cash Equivalents and Short-Term Investments	6.78M	14.36M	4.31M	6.55M	9.45M	12.04M
Total Debt	3.09M	0.00	10.27M	18.76M	0.00	0.00
Total Liabilities	7.13M	4.13M	12.96M	20.92M	2.47M	2.10M
Stockholders Equity	61.02M	70.13M	48.51M	40.31M	56.30M	53.65M
Cash Flow
Free Cash Flow	-10.94M	-11.50M	-15.68M	-21.71M	-20.32M	-18.93M
Operating Cash Flow	-10.94M	-11.50M	-15.68M	-19.10M	-15.60M	-11.69M
Investing Cash Flow	-6.63M	-6.50M	-5.10M	-2.61M	-4.73M	-7.23M
Financing Cash Flow	14.32M	28.05M	18.54M	18.80M	17.73M	0.00

aXichem AB Class A Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.76
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:AXIC.A, the sentiment is Neutral. The current price of 2.76 is below the 20-day moving average (MA) of 3.13, below the 50-day MA of 3.15, and above the 200-day MA of 2.18, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 57.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:AXIC.A.

aXichem AB Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
AXIC.A	59 Neutral	€164.34M	―	-32.52%	―	64.85%	44.62%
NEXAM	46 Neutral	€303.43M	―	-7.96%	―	-1.89%	-59.17%
TRIBO.B	45 Neutral	€43.10M	―	-17.94%	―	9.05%	81.56%
ORGC	42 Neutral	kr193.61M	―	-74.60%	―	-16.35%	-33.91%